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Abstract
To develop avian influenza H5N1 recombinant protein, the hemagglutinin (HA), neuraminidase
(NA), matrix (M), and non-structural (NS1) of avian influenza H5N1 isolates from Thailand were
engineered to be expressed in prokaryotic (E. coli) and mammalian cell (COS-7) system. The
plasmid pBAD-His and pSec-His were used as vectors for these inserted genes. Mice immunized
with purified recombinant proteins at concentration 50–250 µg intramuscularly with Alum adjuvant
at week 0, week 2, and week 3 showed a good immunogenicity measured by ELISA and
neutralization assay. The HA and NS recombinant proteins produced in COS-7 cells can induce
specific antibody titer detected by neutralization assay significantly higher than corresponding
recombinant proteins produced in E. coli system. The antibody produced in immunized mice could
neutralize heterologous avian influenza virus determined by micro-neutralization assay. This study
shows that avian influenza virus H5N1 recombinant proteins produced in mammalian cell system
were able to induce neutralizing antibody response.
Introduction
From January 2004, the pandemic of highly pathogenic
avian influenza H5N1 (AI) in poultry and human had
started from 9 Asian countries, such as Cambodia, China,
Indonesia, Japan, Laos, Malaysia, South Korea, Thailand,
and Vietnam [1]. It has expanded worldwide. In Thailand,
a total of 22 human infected cases were reported until
present with the last case detected in November 2005. The
development of prevention avian influenza vaccine was
ongoing by based on concept of influenza vaccine includ-
ing inactivated or subunit virus grown in embryonated
chicken eggs and recombinant technology including
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DNA, peptide, recombinant protein, live vector vaccines
[2-6]. However, concerns about safety, mass production,
preexisting immunity in people, immune responses
against vector itself, the use of purified recombinant avian
influenza hemagglutinin and neuraminidase proteins
appear to be a promising alternative. The H5N1 vaccines
were developed and trial. The controversial of using avian
influenza vaccine in the poultry is still under discussion in
Thailand.
Because hemagglutinin (HA) protein is a major viral sur-
face antigen against neutralizing antibodies elicited,
recombinant HA was a target as a candidate avian influ-
enza vaccine. The mammalian cell (COS-7 cell line) and
prokaryotic cell (E. coli) were used as the expression cell
system for recombinant HA protein production. Also, the
recombinant neuraminidase (NA) protein, the other viral
surface protein, and nucleocapsid protein (M), and non-
structural (NS1) protein, were also produced. The purified
proteins, rHA5, rNA1, rNS1, and rM, produced from E.
coli and COS-7 cellls, were administered in mice in com-
bination with adjuvant, was capable of eliciting antibody
specific for avian influenza virus, detected by ELISA and
neutralizing antibody assay.
Materials and methods
Virus
Avian influenza virus (H5N1) isolates from Thailand were
selected and the nucleotide sequences of hemagglutinin
(HA), neuraminidase (NA), matrix (M), and non-struc-
tural (NS) genes were identified as H5 and N1 with the
accession number: A/Thailand/HA20/2005 (DQ885618),
A/Thailand/M38/2005 (DQ885619Q), A/Thailand/
NA60/2005 (DQ885620), and A/Thailand/NS49/2005
(DQ885621), respectively. All viruses were grown in
MDCK cell line and processed in biosafety level 3 contain-
ment by trained lab technicians. Viral RNA was extracted
from culture supernatant by using QiaAamp viral RNA
mini kit (Qiagen, Germany).
Cloning of avian influenza virus genes (HA, NA, NS, M)
After cDNA was amplified from viral RNA lysate with uni-
versal primer (5'-AGCAAAAGCAGG-3') by RT-PCR using
Superscript III One step RT PCR (Invitrogen, USA). PCR
was used to amplify HA gene with forward primer (5'-CTC
GAG GAT ATC CAA AAG CAG GGG TCC GAT CT-3') and
reverse primer (5'-AAG CTT GCG GCC GCC AAT GAC
CCA TTG GAA CA-3'), NA gene with forward primer (5'-
CTG CAG AAG CTT AGC AAA AGC AGG AGT-3') and
reverse primer (5'-GAA TTC GCG GCC GCG TAC TTG
TCA ATG GTG A-3'), M gene with forward primer (5'-GAG
CTC GAT ATC ATG AGT CTT CTA ACC GAG GTC-3') and
reverse primer (5'-GAA TTC GCG GCC GCC TTG AAT
CGC TGC ATT TGC AC-3'), and NS gene with forward
primer (5'-CTC GAG GAT ATC AGC AAA AGC AGG GTG-
3') and reverse primer (5'-GAA TTC GCG GCC GCC CAT
CTT ATC TCT TGA-3'). The expected amplified size of HA,
NA, M, and NS1 genes are 1778 bps, 1413 bps, 1027 bps,
and 890 bps, respectively.
PCR was performed for 3 cycles, each consisted of 94°C
denaturation step for 1 min (6 min for first cycle), 55°C
annealing step for 1 min, and 72°C extension step for 1
min, followed by 31 cycles of 94°C for 15 sec, 55°C for
45 sec, 72°C for 90 sec and the final extension at 72°C for
10 min in both of first round and second round PCR. The
amplified products were cloned into vector pGEM-T
(Promega, USA) and subcloned into pBAD/His C vector
(Invitrogen, USA.) and used to transform LMG194 com-
petent E. coli cells. All colonies of E. coli containing pBAD/
His-HA, pBAD/His-NA, pBAD/His-M, pBAD/His-NS1,
were checked for positive clones containing insert frag-
ment of and by digestion plasmid DNA with restriction
enzymes, Pst I and EcoRI.
To construct the mammalian expression vector, pSecTag2/
Hygro C (Invitrogen, USA.) for HA, NA, M, and NS1 pro-
tein expression in COS-7 cell line, the XhoI/ApaI digested
DNA from pBAD/His-HA or pBAD/His-NA or pBAD/His-
NS or pBAD/His-M was subcloned into digested
pSecTag2/Hygro C vector to produce pSec-His-HA, pSec-
His-NS1 and pSec-His-NA. The pBAD/His-HA, pBAD/
His-NA, pBAD/His-NS1, pBAD/His-M DNA was used for
transformation into DH5α competent E. Coli cells and
pSec-His-HA, pSec-His-NS1 and pSec-His-NA DNA to
transform COS-7 cell line by using polyfect transfection
system (Qiagen, USA).
Recombinant protein expression and purification [7,8]
Overnight culture of E. coli strain LMG containing pBAD/
His-HA or pBAD/His-NA or pBAD/His-NS1 or pBAD/His-
M was added to a final of 0.2% to induce the production
of polyhistidine tagged protein and the recombinant pro-
tein was extracted and purified by metal affinity column,
MagneHis™ protein purification system (Promega, USA),
to purify the polyhistidine tagged protein.
The stably expressed pSec-His-HA, pSec-His-NS1, pSec-
His-M and pSec-His-NA in COS-7 cell lines in medium
containing 200 µg/ml of hygromycin B were lysed with
lysozyme. The cell lysate was used to purify recombinant
protein with MagneHis™ protein purification system
(Promega, USA). The recombinant HA, NA, NS, M pro-
teins were detected by SDS-PAGE analysis (3.85% stack-
ing gel and 10% separating gel with a constant voltage of
150 volts for 1 hour) and followed by Western blot anal-
ysis against mouse anti-Xpress serum (Invitrogen, USA) as
previously described [8].Journal of Immune Based Therapies and Vaccines 2007, 5:10 http://www.jibtherapies.com/content/5/1/10
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Immunization of mice
Animal usage in this study was performed according to
the national guidelines and instructional policies. Mice
were purchased from the National Laboratory Animal
Center, Thailand. Six to eight-week-old pathogen-free,
female Balb/c mice were used for vaccination. The ani-
mals were housed in a temperature controlled environ-
ment at 22–24°C with 12 h day-night cycles, and received
food and water ad libitum. Mice were immunized three
times intramuscularly (IM) at 1-week interval with 200 µl
doses of 50, 100, 150, 200, and 250 µg of rHA, rNA, rNS1,
and rM protein produced in E. coli and COS-7 cells plus
an emulsion prepared with Alum adjuvant. Two mice
were injected with pSecHis/HygroC vector protein as con-
trol. Boosts were given at 2 and 3 weeks after the first
immunization. One week after the last boosting, mice
were sacrificed and whole blood was collected for immu-
nogenicity analysis. Then, 250 µg of rHA, rNA, rNS1, and
rM protein produced in E. coli and COS-7 cells were
selected to immunize 5 groups of mice (5 mice/group) for
each protein and boosted as described. Serum was pre-
pared by centrifugation of clotted blood at 1800 × g for 5
min, stored at -80°C until used.
Detection of H5N1 specific antibody from immunized mice 
sera [9]
ELISA
The presence of serum anti-HA, -NA, -NS1, -M specific
immunoglobulins was determined by an enzyme linked
immunosorbent assay (ELISA). Briefly, 500 µl of purified
HA or NA, or NS or M proteins were incubated with 50 µl
of MagnaHis bead (Promega, USA) and 5 µg/ml of bead
solution was added to each 96-well plates. Diluted mice
sera in blocking solution (PBS/Tween 20 containing 5%
skim milk) were added after 5 times washing. The horse-
radish peroxidase-labeled goat anti-mouse Ig(G+M+A)
diluted 1:1000 in blocking solution and 100 µl of TMB
substrate were used for ELISA. Reactions were stopped by
adding 100 µl of 1 N H2SO4. The absorbance was meas-
ured at 450 nm with an ELISA microplate reader. The cut
off value of absorbance was calculated as formula: cut off
= 0.124 [(X+3SD) × 2], X = mean of all negative samples
absorbance +3 standard deviation) × 2. ELISA index (EI =
Absorbance/cut off) is a ratio of absorbance value of any
sera and cut off value. EI of any area is less than 1, inter-
pretation is negative, and EI ≥ 1 means positive result.
Micro neutralization assay [10]
The H5N1 virus, A/Thailand/RPNP/2005 (DQ885616)
with tissue infectious dosage 50 (TCID50) per ml were
incubated with diluted mice serum samples twofold in
medium, from 1:4 to 1:2560. Mixtures of virus and serum
were transferred to monolayers of MDCK cells and incu-
bated for one hour at 37°C in 5% CO2 for 3 days. After
three days, cell medium was incubated with 100 µl of
monoclonal antibodies directed against the influenza
type A or type B nucleocapsid antigen (Chemicon Europe,
Hampshire, UK). After incubation for 60 min at 37°C and
washing, affinity-purified peroxidase-conjugated, goat
anti-mouse IgG (Jackson ImmunoResearch Europe, Cam-
bridgeshire, UK), was added and the plates were incu-
bated at room temperature for 120 min. After being
washed, 100 µl substrate (orthophenylenediamine) was
added, and the enzyme reaction was stopped after 30 min
with 100 µl 2.5 M sulfuric acid. The reaction was quanti-
fied by measuring the OD at wavelength 492 nm. The
neutralization (NT) titers were defined as the inverted
value of the serum dilution giving ≥ 50% OD reduction
compared to the virus control.
Result
Characterization of HA, NA, NS, and M recombinant 
proteins from E. coli and Cos7 cell system
The recombinant proteins were purified by affinity chro-
matography using paramagenetic precharged nickel parti-
cles (MagneHis™ Ni-particles). The 63, 50, 30, and 26
Kdal of recombinant HA, NA, M, and NS1 protein pro-
duced in E. coli system were detected by immunoblot
hybridization assay against anti-Xpress antibody. Then,
these HA, NA, M and NS genes in E. coli plasmid system
were transferred to pSec/His mammalian cell system. The
70, 55, 36, and 30 Kdal of HA, NA, M, NS1 recombinant
protein produced in mammalian cell system were
detected by Western blot hybridization against anti-
Xpress antibody as shown in Fig 1. Only the recombinant
proteins from the clones that were expressed in both E.
coli and mammalian system were used for further immu-
nogenicity study. The yield of recombinant proteins HA
(rHA5) and NA (rNA1) produced by pBAD-His-HA,
pBAD-His-NA in E. coli system and pSec-His-HA and
pSec-His-NA in mammalian cell system were 0.5 mg per
Immunoblot analysis of recombinant HA, NA, M, NS1 pro- teins produced in COS-7 cells against anti-Xpress antibody Figure 1
Immunoblot analysis of recombinant HA, NA, M, NS1 pro-
teins produced in COS-7 cells against anti-Xpress antibody. 
The molecular weight of recombinant HA, NA, M, and NS1 
were shown in kD as 70, 55, 36, and 30 KD, respectively.Journal of Immune Based Therapies and Vaccines 2007, 5:10 http://www.jibtherapies.com/content/5/1/10
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100 ml bacterial culture and 0.05 mg per 100 ml cells,
respectively.
Immunity in immunized mice
To determine the optimal concentration of HA, NA, M, NS
recombinant proteins to induce immunogenicity, the
recombinant proteins at 50–250 microgram were used to
immunize mice. The specific antibody response against
avian influenza virus antigen of HA, NA, M, NS1 recom-
binant protein immunized mice was determined by ELISA
and shown in dose responsive curve in Fig 2. The NS1
recombinant protein produced from COS-7 cells (rNS/
COS-7) gave highest antibody response titer measured by
ELISA at dose 250 µg, while M recombinant protein gave
lowest immunogenicity even increasing dose to 250 µg.
The optimal dose at 250 µg of all recombinant proteins
with Alum adjuvant was selected to use for comparing the
specific antibody elicit in mice determined by ELISA and
neutralization antibody assay. The HA and NS recom-
binant proteins produced in COS-7 cells can induce spe-
cific antibody titer detected by neutralization assay
significantly higher than corresponding recombinant pro-
teins produced in E. coli system at 250 µg as shown in
Table 1. The NS1/COS-7 cells recombinant protein can
induce ELISA and neutralizing antibody titer higher sig-
nificantly than any other recombinant proteins. Even the
antibody response measured by ELISA in rNA protein/
COS-7 cells immunized mice was significantly higher
than that produced in E. coli system, but their neutralizing
antibody responses were not different. This result shows
that avian influenza virus H5N1 heterologous strain
could be neutralized by recombinant HA, NA, and NS
proteins immunized sera from mice in vitro.
Discussion
The mammalian COS-7 cell system has successfully used
as host for the efficient production of avian influenza
virus (H5N1) proteins including hemagglutinin (HA),
neuraminidase (NA), matrix (M), and non-structural
(NS1) proteins with yield of 0.05 mg per 100 ml cells.
These recombinant proteins could elicit specific antibody
response against avian influenza virus (H5N1) antigen
tested by ELISA. The protecting antibody in vitro, which
was determined by neutralizing antibody assay, was also
developed in animal immunized with HA, NA and NS
recombinant proteins. Comparing between recombinant
proteins produced in E. coli and COS-7 cell, we found that
at the same concentration, recombinant protein produced
from COS-7 cells could induce significantly higher anti-
body response measured by ELISA and neutralization
assay. The recombinant viral proteins production from
mammalian cell system are modified similarly to those
naturally produced in viral infected human cells [11,12].
So, the antigenic epitopes are not different from the chal-
lenging heterologous virus used in neutralization assay.
However, recombinant NS protein produced from COS-7
cells showed highest antibody response measured by
ELISA and neutralization assay. The NS1 protein is
encoded in the shortest segment of the viral genome and
is abundant in influenza virus-infected cells, but it has not
been detected in virions [13]. The protein is found pre-
dominantly in the nucleus and has pleiotropic activities
such as shutting off the host protein synthesis, supporting
the translation of the late viral proteins, inhibiting pre-
Dose responsive curve of antibody response in immunized  mice Figure 2
Dose responsive curve of antibody response in immunized 
mice. Sera from 5 mice per group were collected 1 week 
after last immunization and tested by ELISA for the presence 
of specific antibodies by using recombinant HA or NA, or NS 
or M proteins. Antibody titers are expressed as the log2 val-
ues of reciprocal endpoint titers. (a) Antibody titers of sera 
from mice immunized with recombinant HA, NA, M, and NS 
proteins produced in mammalian (COS-7) cell system; 50, 
100, 150, 200 and 250 µg. (b) Antibody titers of sera from 
mice immunized with recombinant HA, NA, M, and NS pro-
teins produced in prokaryotic (E. coli) cell system; 50, 100, 
150, 200 and 250 µg.
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mRNA splicing, regulating the nuclear transport of
mRNA, or exhibiting interferon antagonistic activity.
We have shown that immunogenic potential of recom-
binant HA, NA and NS1 proteins produced from COS-7
cells as described here, may be appropriate for further
development of an avian influenza virus vaccine that
could elicit the cross-reactive neutralizing antibody. This
result was preliminary for further proof by challenging
study in animals.
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Table 1: Neutralizing antibody titer (NT titer) (geometric mean) of sera from immunized mice against heterologous H5N1 influenza 
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immunization with 250 µg of recombinant HA or NA, or NS1 or M proteins. Mann-Whitney method
Recombinant proteins Neutralization titer ELISA titer
GMT (± SD) P GMT (± SD) P
NA/COS-7 34 (± 8) 0.36 160 (± 78) 0.01
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HA/COS-7 91.8 (± 35.7) 0.01 422 (± 175) 0.28
HA/E. coli 22 (± 8) 160 (± 87)
NS1/COS-7 139* (± 35) 0.01 1688* (± 701) 0.01
NS1/E. coli 22 (± 8) 422 (± 175)
M/COS-7 0 NA 40 (± 21) 0.1
M/E. coli 02 2  ( ±  8 )
*Significant (P < 0.05, Mann-Whitney method, NS/COS-7 and other proteins)